Benzinga
Benzinga
Benzinga
martedì, settembre 29

Belite Bio Inc

BLTENASDAQ
Trade with Public
Trade with Public
$165.93
In chiusura: Sep 29, 5:00 PM EST
$165.93
N/A
Post-mercato: 4:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaRapporto azionario

Belite Bio Analyst Price Targets

Wall Street analyst price targets and consensus rating for Belite Bio (BLTE).

Price Target Range — 12 Quarters

Analyst Consensus — 8 Analysts

8Buy
Consensus RatingBuy# Analysts8Avg. Consensus PT$197Upside to Avg. PT+18.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026MizuhoGraig SuvannavejhPT RaiseOutperform$220→$234
Sep 8, 2026HC Wainwright & Co.Yi ChenPT RaiseBuy$214→$245
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Mizuho Maintains Outperform on Belite Bio, Raises Price Target to $234

Mizuho analyst Graig Suvannavejh maintains Belite Bio (NASDAQ:BLTE) with a Outperform and raises the price target from $220 to $234.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $245

HC Wainwright & Co. analyst Yi Chen maintains Belite Bio (NASDAQ:BLTE) with a Buy and raises the price target from $214 to $245.
Benzinga Newsdesk

Why Is Belite Bio Stock Soaring Friday?

Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.
Vandana Singh

This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday

Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
Avi Kapoor

PRO
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303

Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206

Morgan Stanley analyst Judah Frommer maintains Belite Bio (NASDAQ:BLTE) with a Overweight and raises the price target from $201 to $206.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved